

Table S2. Dose-Response Evaluation of Selected ASD Prototypes in the TMEV Model: Seizures Observed at the Time of Drug Injection.

Compound	Dose mg/kg, IP	% VEH Cumulative Seizure Burden
Carbamazepine	10	141 ± 19
	20	72 ± 17
	40 ^a	40.6 ± 13.8
Ethosuximide	300 ^a	112 ± 20.2
	400	61.3 ± 12.6
Levetiracetam	10	54.1 ± 8.7
	30	33.9 ± 7.5**
	350	35.9 ± 7.0**
	700	21.9 ± 4.9****
	1000 ^a	11.3 ± 5.4****
Phenytoin	2.5	112.9 ± 16.9
	5	80.5 ± 17.4
	10	84.0 ± 15.0
	20 ^a	15.6 ± 4.5**
Ezogabine	15	47.3 ± 16.2
	20 ^a	46.8 ± 8.1**
Sodium Valproate	50	77.9 ± 18.4
	100	51.3 ± 15.1
	200	52.3 ± 15.9
	239 ^a	0.6 ± 0.6****
Phenobarbital	20	4.0 ± 3.0***
	35 ^a	1.7 ± 1.3****

^aData from Table 1.

P<0.01, *P<0.001, ****P<0.0001 compared to VEH seizure burden from the same testing cohort; Mann-Whitney U test.